Gilead Sciences, a privately owned company headquartered in the US, was founded in 1987. With approximately 13,690 employees, the company functions as a tier 1 media tech buyer. Gilead Sciences specializes in biotechnology research, focusing on bringing forward medicines for life-threatening diseases. The company's operations involve its employees collaborating through science to address medical challenges.
On July 31, 2026, a government health department revealed plans for local manufacturing of Gilead's twice-yearly HIV prevention injection, lenacapavir, by shortlisting three domestic pharmaceutical companies to produce a generic version for wider regional access, following increasing calls for greater availability. On the same day, Erste Group Bank analysts cut their FY2027 EPS estimates for Gilead Sciences. This follows news on July 30, 2026, that a once-weekly single-tablet regimen combining islatravir and lenacapavir maintained viral suppression in people with HIV who switched from standard daily oral treatment. These findings were presented at the 26th International AIDS Conference (AIDS 2026) in Rio de Janeiro.
Similar Companies
Subscribe for full access to Gilead Sciences's profile
Gilead Sciences offers 2 products in the media and telecoms services industry. Gilead Sciences's product portfolio comprises of search, social, and retail media.
Subscribe for full access to Gilead Sciences's products in full detail
Subscribe for full access to Gilead Sciences's revenue in full detail
Subscribe for full access to Gilead Sciences's products in full detail 
